Search the Newsreel

National CineMedia (NCMI): Orbis and Allan Gray disclose 9.9% beneficial stake in amended 13G

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed an amended 13G filing for National CineMedia, Inc. (NCMI), reporting a combined beneficial ownership of 9.9% of the company's common stock, totaling 9,313,977 shares. Orbis holds sole voting and dispositive power …

Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5.5% ownership stake in Praxis Precision Medicines (PRAX), amounting to 1,529,788 shares of common stock as of June 30, 2026. Orbis holds the majority with 1,526,680 shares, while Allan Gray …

JPMorgan cuts Cinemark to Neutral, trims price target (CNK:NYSE)

JPMorgan downgraded Cinemark Holdings (CNK) to Neutral from Overweight and reduced its price target from $40 to $39. The downgrade reflects JPMorgan's view that the movie exhibitor's recovery thesis has largely played out. Following the news, shares of Cinemark Holdings slipped approximately 2%.

(PRAX) and the Role of Price-Sensitive Allocations

This article provides a detailed AI-driven analysis of Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting a strong overweight bias across all time horizons. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report …

Cinemark Holdings (NYSE: CNK) director Burian files initial Form 3 ownership

Cinemark Holdings (NYSE: CNK) director Lawrence J. Burian has filed an initial Statement of Beneficial Ownership (Form 3), indicating his status as a reporting person. The filing confirms that Burian is a director but reports no equity transactions, derivative positions, or holding entries for …

Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake

Squadron Master Fund LP and related entities, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have reported a beneficial ownership stake of 810,000 shares in Lipocine Inc. (LPCN). This represents 9.8% of the company's outstanding shares as of May 6, 2026. The …

Why Is Cintas (CTAS) Down 2.7% Since Last Earnings Report?

A month has gone by since the last earnings report for Cintas (CTAS). Shares have lost about 2.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings …

Did Cintas’ (CTAS) New President–COO Structure Quietly Reframe Its Operational Edge and Investment Narrative?

Cintas Corporation recently restructured its leadership, appointing Jim Rozakis as President and COO, while Todd Schneider remains CEO focusing solely on that role. This separation is seen as governance fine-tuning rather than a material shift in the company's investment narrative, which still emphasizes recurring …

New Ray Medicine Sets August Board Meeting to Review Interim Results and Dividend

Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform

Following a decade of exploration from the 2014 NVIDIA GTC to the PreciousGPT model series, Insilico Medicine presents the industry's first multi-agent Virtual Aging Cell (VAC) platform with biological age as a core condition. CAMBRIDGE, Mass., Aug. 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", …

Everest Medicines Reshapes Board With Director Resignation and New Appointment

Kingworld Medicines Schedules Board Meeting to Review Interim Results and Dividend

National CineMedia, Inc. (NASDAQ:NCMI) Just Reported, And Analysts Assigned A US$4.81 Price Target

National CineMedia, Inc. (NASDAQ:NCMI) recently reported its quarterly results, showing revenues in line with expectations but a significant increase in statutory losses. Analysts have maintained revenue forecasts but have expanded loss-per-share expectations, leading to an 8.3% dip in the average price target to US$4.81. …

Beijing Tong Ren Tang Chinese Medicine Sets Board Meeting to Approve Interim Results and Consider Dividend

Everest Medicines Sets Out Board Structure and Key Governance Committees

BeOne Medicines Sets Audit Committee Review for Dual-Market Interim Results

National CineMedia, Inc. (NASDAQ:NCMI) Given Average Rating of "Hold" by Brokerages

National CineMedia, Inc. (NASDAQ:NCMI) has received a consensus "Hold" rating from six analysts, with an average 12-month price target of $4.81. The company recently reported quarterly results that missed expectations, with a $0.10 per-share loss and revenue of $58.4 million. An insider sold 12,058 …

DANIELI & C. OFFICINE MECCANICHE S.P.A.

Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal

Parabilis Medicines, Inc. reported its Q2 2026 results, showing a significant increase in cash and cash equivalents to over $1.1 billion. This boost follows its June 2026 IPO, which generated $787.9 million in net proceeds, and a $50.0 million upfront payment from its collaboration …

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova (MNOV) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.06 loss and improving from a $0.07 loss a year ago. The company also exceeded revenue estimates, posting $0.46 million against a $0.15 million consensus, though its …

Parabilis Medicines (PBLS) Earnings Date and Reports 2026

Form 8K Parabilis Medicines For: 13 August By Investing.com

The article is a brief financial news item from Investing.com, reporting on a Form 8K filing by Parabilis Medicines for August 13th. It provides no further details beyond stating the filing occurred on that date.

Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000

Parabilis Medicines, Inc. (PBLS) reported its Q2 revenue as $148,000. The company, a clinical-stage biopharmaceutical firm, focuses on developing transformative medicines for "undruggable" protein targets using its proprietary Helicon platform. Analysts currently have a "BUY" consensus for PBLS with an average target price of …

MediciNova (NASDAQ:MNOV) Announces Quarterly Earnings Results

MediciNova (NASDAQ:MNOV) exceeded quarterly earnings expectations, reporting a loss of $0.05 per share against an estimated $0.06 loss, and revenues of $0.46 million, significantly above the $0.07 million forecast. Despite the positive earnings surprise, the company experienced a slight dip in share price to …

nCino Announces Timing of its Second Quarter Fiscal Year 2027 Financial Results Conference Call

nCino, Inc. (NASDAQ: NCNO) will report its second-quarter fiscal year 2027 financial results on Tuesday, August 25, 2026, after the market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss these results. A …

MediciNova: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for MediciNova. No further details are available in the provided content.

Cineverse outlines $13M annual cost cuts while targeting $115M-$120M FY2027 revenue

Earnings Call Insights: Cineverse (CNVS) Q1 fiscal 2027 MANAGEMENT VIEW * "We registered yet another very strong quarter" driven by the Giant Worldwide and IndiCue acquisitions, and "technology revenues represented more than 60% of the consolidated total during the quarter," according to (Chairman & …

Cineverse (NASDAQ:CNVS) Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Is Cineverse Corp (CNVS) Worth the Investment After Q1 Earnings

MNOV: Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027

MediciNova (MNOV) reported a revenue increase to $0.5M in Q2 2026, primarily from Mayo ALS study services, while significantly narrowing its net loss to $2.3M. Research and development expenses decreased year-over-year, and the company's $25.4M in cash reserves are projected to fund operations until …

Earnings call transcript: Cineverse posts Q1 2026 revenue beat, shares edge up

Modern Chinese Medicine Group Sets August Board Meeting for Interim Results and Dividend Review

Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing

Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 13,564,149 shares, or 6.4%, of Revolution Medicines, Inc. (RVMD) common stock, according to a recent Schedule 13G/A filing. This includes 13,550,796 shares and 120,085 common stock purchase warrants, with the …

Cineverse Corp. (CNVS) Stock Rises on Q1 2027 Earnings

Wellington group (CNK) discloses 7.76M Cinemark shares under shared control

Wellington Management Group LLP and its affiliated entities have reported beneficial ownership of 7,755,183 shares of Cinemark Holdings, Inc. common stock, representing 6.69% of the class. The filing, a SCHEDULE 13G/A, indicates that these shares are held with shared voting power over 5,859,465 shares …

Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results